Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)

Author(s):  Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel

Issue:  Jul/Aug 2017 - Volume 21, Number 4
View All Articles in Issue

Page(s):  322-329

Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 1
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 2
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 3
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 4
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 5
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 6
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 7
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Page 8

Download in electronic PDF format for $65

Abstract:  Budesonide is a corticosteroid that has been shown effective in the treatment of eosinophilic esophagitis, but there are currently no commercial medicines to treat this chronic allergic/immune condition, despite its prevalence in the U.S. Therefore, pharmaceutical compounding is the alternative choice to meet the therapeutic need of eosinophilic esophagitis patients. Two budesonide mucoadhesive oral suspensions (1 mg/10 mL and 2 mg/10 mL) were developed using the compounding vehicle MucoLox, a proprietary mucoadhesive polymer blend that promotes mucosal adhesion. The physical and chemical stability of the oral suspensions was tested over a period of 182 days, at room temperature and refrigerated conditions, in order to determine the corresponding beyond-use date. The physical characterization consisted in observing all samples for color/appearance and odor, and testing for pH and density, whereas the chemical characterization consisted in ultra-performance liquid chromatography assay testing. Both oral suspensions were proven physically and chemically stable, and the ultra-performance liquid chromatography method was proven stability indicating. As a result, the beyond-use date of the budesonide 1-mg/10-mL and 2-mg/10-mL mucoadhesive oral suspensions (MucoLox), in amber plastic bottles, is six months at both room temperature and refrigerated conditions.

Related Keywords: Kendice Ip, BA, Maria Carvalho, PharmD, MRPharmS, PhD, Ashley Shan, Daniel Banov, MS, budesonide, corticosteroid, asthma, inflammatory bowel disease, eosinophilic esophagitis, mucoadhesive oral suspensions, mucosal adhesion, anti-inflammatory agent, formulation, physical stability, chemical stability, forced degradation studies, stability-indicating assay, storage

Related Categories: EXCIPIENTS, FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, ALLERGY/IMMUNOLOGY/INFLAMMATION, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice
, Carvalho Maria, Shan Ashley, Banov Daniel
Jul/Aug 2017
Pg. 322-329

Evaluation of the Efficacy and Stability of Compounded Pentoxifylline-containing XemaTop for Psoriasis
Song Guiyun
, Ip Kendice, Shan Ashley, Banov Daniel, Bassani August S
Jul/Aug 2020
Pg. 337-345

Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Frankum James
, Ramsay Dale, Das Nandita G, Das Sudip K
Mar/Apr 2004
Pg. 101-105

Physical and Chemical Stability of Estriol 0.025% to 1% Vaginal Creams (VersaBase)
Ip Kendice
, Shan Ashley, Yan Wei, Banov Daniel
Nov/Dec 2018
Pg. 504-511

Eosinophilic Esophagitis: Treatment with Oral Viscous Budesonide
Zur Eyal
Jul/Aug 2012
Pg. 288-293

Utilization of Compounded Medications in an Oral Medicine Practice
Stock Shannon
, Rubino Katie, Woo Sook-Bon, Margolis Arthur, Thomas Irena, Aboalela Ali, Treister Nathaniel
Mar/Apr 2016
Pg. 155-158

Management of Psoriasis with a XemaTop Topical Compounded Formula: A Case Report
Jones Nat
, Carvalho Maria, Branvold-Herr Andrea
May/Jun 2017
Pg. 205-211

The Treatment of Canine Atopic Disease
Davidson Gigi S
May/Jun 2002
Pg. 210-215

Physicochemical Stability of Extemporaneously Prepared Methylcobalamin Injections in the Presence and Absence of Preservative and the Impact of Light Exposure
Ip Kendice
, Banov Daniel, Bassani Gus, Morgan Latisha
Mar/Apr 2019
Pg. 167-175

Budesonide 0.0.25% Mucoadhesive Gel
Allen Loyd V Jr
Jul/Aug 2021
Pg. 323